HistoSonics has closed a new financing round to support the continued growth of its Edison histotripsy platform, bringing the company’s valuation to $3.75 billion.
The round included participation from Reed Jobs, Yosemite, and strategic investors. The funds will support commercial expansion, clinical development, regulatory activities, and new applications for the technology.
Related: Sonire Therapeutics awarded $13M from Japanese government-backed innovation agency
HistoSonics’ Edison system uses focused ultrasound energy delivered through a robotic platform to perform histotripsy — a non-invasive approach that mechanically destroys and liquefies targeted tumors without traditional surgery or radiation.
The platform received FDA De Novo authorization in 2023 and is currently the only histotripsy system cleared for clinical use globally. Future development areas include treatments for benign prostatic hyperplasia (BPH) and kidney tumors.
CEO Mike Blue said:
“Building a generational company requires partners who bring more than capital.”
The financing strengthens HistoSonics’ efforts to expand adoption of histotripsy and develop new non-invasive treatment applications.
